Current treatment of choroidal melanoma

References

• Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer83(8), 1664–1678 (1998).
   PubMed Web of Science ®Google Scholar
• Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology118(9), 1881–1885 (2011).
   PubMed Web of Science ®Google Scholar
• Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am. J. Ophthalmol.140(4), 612–617 (2005).
   PubMed Web of Science ®Google Scholar
• De Potter P, Shields CL, Shields JA. New treatment modalities for uveal melanoma. Curr. Opin. Ophthalmol.7(3), 27–32 (1996).
   PubMedGoogle Scholar
• Robertson DM. Changing concepts in the management of choroidal melanoma. Am. J. Ophthalmol.136(1), 161–170 (2003).
   PubMedGoogle Scholar
• Shields CL, Shields JA. Clinical features of small choroidal melanoma. Curr. Opin. Ophthalmol.13(3), 135–141 (2002).
   PubMedGoogle Scholar
• Finger PT. The 7th edition AJCC staging system for eye cancer: an international language for ophthalmic oncology. Arch. Pathol. Lab. Med.133(8), 1197–1198 (2009).
   PubMedGoogle Scholar
• Damato B, Coupland SE. Translating uveal melanoma cytogenetics into clinical care. Arch. Ophthalmol.127(4), 423–429 (2009).
   PubMedGoogle Scholar
• Eskelin S, Kivelä T. Uveal melanoma: implications of tumor doubling time (author’s reply). Ophthalmology108(5), 830–831 (2001).
   Google Scholar
• Mashayekhi A, Siu S, Shields CL, Shields JA. Slow enlargement of choroidal nevi: a long-term follow-up study. Ophthalmology118(2), 382–388 (2011).
   PubMed Web of Science ®Google Scholar
• Melia M, Moy CS, Reynold SM et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma. Arch. Ophthalmol.124(2), 226–238 (2006).
   PubMed Web of Science ®Google Scholar
• Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch. Ophthalmol.110(2), 245–250 (1992).
   PubMed Web of Science ®Google Scholar
• Margo CE. The Collaborative Ocular Melanoma Study: an overview. Cancer Control.11(5), 304–309 (2004).
   PubMedGoogle Scholar
• The Collaborative Ocular Melanoma Study Group The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am. J. Ophthalmol.125(6), 779–796 (1998).
   PubMed Web of Science ®Google Scholar
• Hungerford JL. Current trends in the treatment of ocular melanoma by radiotherapy. Clin. Experiment. Ophthalmol.31(1), 8–13 (2003).
   PubMed Web of Science ®Google Scholar
• Karlsson UL, Augsburger JJ, Shields JA et al. Recurrence of posterior uveal melanoma after 60Co episcleral plaque therapy. Ophthalmology96(3), 382–388 (1989).
   PubMedGoogle Scholar
• Munzenrider JE, Verhey LJ, Gragoudas ES et al. Conservative treatment of uveal melanoma: local recurrency after proton beam therapy. Int. J. Radiat. Oncol. Biol. Phys.17(3), 493–498 (1989).
   PubMed Web of Science ®Google Scholar
• Wilkes SR, Gragoudas ES. Regression patterns of uveal melanoma after proton beam irradiation. Ophthalmology89(7), 840–844 (1982).
   PubMedGoogle Scholar
• Augsburger JJ, Shields JA. Cataract surgery following cobalt-60 plaque radiotherapy for posterior uveal malignant melanoma. Ophthalmology92(6), 815–822 (1985).
   PubMedGoogle Scholar
• Finger PT, Buffa A, Mishra S, Berson A, Bosworth JL, Vikram B. Palladium 103 plaque radiotherapy for uveal melanoma. Clinical experience. Ophthalmology101(2), 256–263 (1994).
   PubMedGoogle Scholar
• Lommatzsch PK. Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators. Surv. Ophthalmol.97(3), 428–429 (1977).
   Google Scholar
• Packer S, Rotman M. Radiotherapy of choroidal melanoma with iodine-125. Ophthalmology87(6), 582–590 (1980).
   PubMed Web of Science ®Google Scholar
• Bonnett DE, Kacperek A, Sheen MA, Goodall R, Saxton TE. The 62 MeV proton beam for the treatment of ocular melanoma at Clatterbridge. Br. J. Radiol.66(790), 907–914 (1993).
   PubMedGoogle Scholar
• Raju MR. Proton radiobiology, radiosurgery and radiotherapy. Int. J. Radiat. Biol.67(3), 237–259 (1995).
   PubMed Web of Science ®Google Scholar
• Verschueren KM, Creutzberg CL, Schalij-Delfors NE et al. Long-term outcomes of eye-conserving treatment with ruthenium(106) brachytherapy for choroidal melanoma. Radiother. Oncol.95(3), 332–338 (2010).
   PubMed Web of Science ®Google Scholar
• Packer S, Rotman M, Fairchild RG, Albert DM, Atkins HL, Chan B. Irradiation of choroidal melanoma with iodine 125 ophthalmic plaque. Arch. Ophthalmol.98(8), 1453–1457 (1980).
   PubMed Web of Science ®Google Scholar
• Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT. Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology99(5), 767–773 (1992).
   PubMed Web of Science ®Google Scholar
• Sealy R, le Roux PL, Rapley F, Hering E, Shackleton D, Sevel D. The treatment of ophthalmic tumours with low-energy sources. Br. J. Radiol.49(582), 551–554 (1976).
   PubMed Web of Science ®Google Scholar
• Pe’er J. Ruthenium-106 brachytherapy. In: Current Concepts in Uveal Melanoma First Edition. Jager MJ, Desjardins L, Kivelä T, Damato BE (Eds). S Karger, Basel, Switzerland, 27–40 (2011).
   Google Scholar
• Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology110(11), 2223–2234 (2003).
   PubMed Web of Science ®Google Scholar
• Collaborative Ocular Melanoma Study (COMS) Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch. Ophthalmol.124(12), 1684–1693 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology106(8), 1579–1587 (1999).
   PubMed Web of Science ®Google Scholar
• Kreusel KM, Bechrakis N, Riese J, Krause L, Wachtlin J, Foerster MH. Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regression and early complications. Graefes Arch. Clin. Experiment. Ophthalmol.244(12), 1575–1580 (2006).
   PubMedGoogle Scholar
• Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after Ru-106 brachytherapy of choroidal melanoma. Int. J. Radiat. Oncol. Biol. Phys.63(2), 385–391 (2005).
   PubMed Web of Science ®Google Scholar
• Verschueren KM, Creutzberg CL, Schalij-Delfos NE et al. Long term outcomes of eye-conserving treatment with ruthenium106 brachytherapy for choroidal melanoma. Radiother. Oncol.95(3), 332–338 (2010).
   PubMed Web of Science ®Google Scholar
• Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology.106(8), 1579–1587 (1999).
   PubMed Web of Science ®Google Scholar
• Frenkel S, Hendler K, Peer J. Uveal melanoma in Israel in the last two decades: characterization, treatment and prognosis. Isr. Med. Assoc. J.11(5), 280–285 (2009).
   PubMedGoogle Scholar
• Rouberol F, Roy P, Kodjikian L, Gerard JP, Jean-Louis B, Grange JD. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays). Am. J. Ophthalmol.137(5), 893–900 (2004).
   PubMed Web of Science ®Google Scholar
• Brown GC, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation retinopathy. Ophthalmology89(12), 1494–1501 (1982).
   PubMed Web of Science ®Google Scholar
• Brown GC, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation optic neuropathy. Ophthalmology89(12), 1489–1493 (1982).
   PubMedGoogle Scholar
• Char DH, Lonn LI, Margolis LW. Complications of cobalt plaque brachytherapy for choroidal melanomas. Am. J. Ophthalmol.84(4), 536–541 (1977).
   PubMed Web of Science ®Google Scholar
• Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology100(10), 1547–1554 (1993).
   PubMed Web of Science ®Google Scholar
• Quivey JM, Char DH, Phillips TL, Weaver KA, Castro JR, Kroll SM. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int. J. Radiat. Oncol. Biol. Phys.26(4), 613–618 (1993).
   PubMedGoogle Scholar
• Lumbroso-Le Rouic L, Charif Chefchaouni M, Levy C et al. 125I plaque brachytherapy for anterior uveal melanomas. Eye18(9), 911–916 (2004).
   PubMedGoogle Scholar
• Puusaari I, Heikkonen J, Kivelä T. Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology111(9), 1768–1777 (2004).
   PubMedGoogle Scholar
• Cogan DG, Donaldson DD, Reese AB. Clinical and pathological characteristics of radiation cataract. AMA Arch. Ophthalmol.47(1), 55–70 (1952).
   PubMedGoogle Scholar
• Miller NR. Radiation-induced optic neuropathy: still no treatment. Clin. Experiment. Ophthalmol.32(3), 233–235 (2004).
   PubMedGoogle Scholar
• Toivonen P, Kivelä T. Pigmented episcleral deposits after brachytherapy of uveal melanoma. Ophthalmology113(5), 865–873 (2006).
   PubMedGoogle Scholar
• Fukushima S, Inoue T, Inoue T, Ozeki S. Postoperative irradiation of pterygium with 90Sr eye applicator. Int. J. Radiat. Oncol. Biol. Phys.43(3), 597–600 (1999).
   PubMed Web of Science ®Google Scholar
• Sener EC, Kiratli H, Gedik S, Sanac AS. Ocular motility disturbances after episcleral plaque brachytherapy for uveal melanoma. J. AAPOS8(1), 38–45 (2004).
   PubMed Web of Science ®Google Scholar
• Al Mahmoud T, Mansour M, Deschenes J et al. Intra-operative echographic localization for radio active ophthalmic plaques in choroidal melanoma. Ann. NY Acad. Sci.1138, 10–14 (2008).
   PubMedGoogle Scholar
• Finger PT. Radiation retinopathy is treatable with antivascular endothelial growth factor bevacizumab (Avastin). Int. J. Radiat. Oncol. Biol. Phys.70(4), 974–977 (2008).
   PubMed Web of Science ®Google Scholar
• Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch. Ophthalmol.125(6), 751–756 (2007).
   PubMedGoogle Scholar
• Brockhurst RJ. Tantalum buttons for localization of malignant melanoma in proton therapy. Ophthalmic Surg.11(5), 352 (1989).
   Google Scholar
• Paganetti H, Niemierko A, Anculiewicz M et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int. J. Radiat. Biol. Phys.53(2), 407–421 (2002).
   PubMed Web of Science ®Google Scholar
• Lumbroso-Le Rouic L, Delacroix S, Dendale R et al. Proton beam therapy for iris melanomas. Eye20(11), 1300–1305 (2006).
   PubMedGoogle Scholar
• Damato B, Kacperek A, Chopra M et al. Proton beam radiotherapy of iris melanoma. Int. J. Rad. Oncol. Biol. Phys.63(1), 109–115 (2005).
   PubMed Web of Science ®Google Scholar
• Egger E, Zografos L, Schalenbourg A et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int. J. Radiat. Oncol. Biol. Phys.55(4), 867–880 (2003).
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Egan KM, Walsh SM, Regan S, Munzenrider JE, Taratuta V. Lens changes after proton beam irradiation for uveal melanoma. Am. J. Ophthalmol.119(2), 157–164 (1995).
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Goitein M, Verhey L et al. Proton beam irradiation of uveal melanomas. Results of 5 1/2-year study. Arch. Ophthalmol.100(6), 928–934 (1982).
   PubMedGoogle Scholar
• Crawford JB, Char DH. Histopathology of uveal melanomas treated with charged particle radiation. Ophthalmology94(6), 639–643 (1987).
   PubMedGoogle Scholar
• Kim MK, Char DH, Castro JL, Saunders WM, Chen GT, Stone RD. Neovascular glaucoma after helium ion irradiation for uveal melanoma. Ophthalmology93(2), 189–193 (1986).
   PubMedGoogle Scholar
• Modorati G, Miserocchi E, Galli L, Picozzi P, Rama P. Gamma knife radiosurgery for uveal melanoma: 12 years of experience. Br. J. Ophthalmol.93(1), 40–44 (2009).
   PubMed Web of Science ®Google Scholar
• Fakiris AJ, Lo SS, Henderson MA et al. Gamma-knife-based stereotactic radiosurgery for uveal melanoma. Stereotact. Funct. Neurosurg.85(2–3), 106–112 (2007).
   PubMed Web of Science ®Google Scholar
• Tokuuye K, Akine Y, Sumi M, Kagami Y, Ikeda H, Kaneko A. Fractionated stereotactic radiotherapy for choroidal melanoma. Radiother. Oncol.43(1), 87–91 (1997).
   PubMed Web of Science ®Google Scholar
• Muller K, Nowak PJ, de Pan C et al. Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. Int. J. Radiat. Oncol. Biol. Phys.63(1), 116–122 (2005).
   PubMed Web of Science ®Google Scholar
• Muller K, Naus N, Nowak PJ et al. Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results. Radiother. Oncol.102(2), 219–224 (2012).
   PubMed Web of Science ®Google Scholar
• Muller K, Nowak PJ, Luyten GP, Marijnissen JP, de Pan C, Levendag P. A modified relocatable stereotactic frame for irradiation of eye melanoma: design and evaluation of treatment accuracy. Int. J. Radiat. Oncol. Biol. Phys.58(1), 284–291 (2004).
   PubMedGoogle Scholar
• Dunavoelgyi R, Dieckmann K, Gleiss A et al. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int. J. Radiat. Oncol. Biol. Phys.81(1), 199–205 (2011).
   PubMed Web of Science ®Google Scholar
• Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, Bleeker JC. Transpupillary thermotherapy in choroidal melanomas. Arch. Ophthalmol.113(3), 315–321 (1995).
   PubMedGoogle Scholar
• Shields CL, Shields JA, DePotter P, Kheterpal S. Transpupillary thermotherapy in the management of choroidal melanoma. Ophthalmology103(10), 1642–1650 (1996).
   PubMed Web of Science ®Google Scholar
• Leeper D. Molecular and cellular mechanism of hyperthermia alone or combined with other modalities. In: Hyperthermic Oncology, Volume 2. Overgaard J (Ed.). Taylor and Francis, Ltd, London, UK, 9–40 (1985).
   Google Scholar
• Reinhold HS. Physiological effects of hyperthermia. Recent Results Cancer Res.107, 32–43 (1988).
   PubMedGoogle Scholar
• Rem AI, Oosterhuis JA, Journée-de Korver HG, van den Berg TJ, Keunen JE. Temperature dependence of thermal damage to the sclera: exploring the heat tolerance of the sclera for transscleral thermotherapy. Exp. Eye Res.72(2), 153–162 (2001).
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Cater J et al. Transpupillary thermotherapy for choroidal melanoma: tumor control and visual results in 100 consecutive cases. Ophthalmology105(4), 581–590 (1998).
   PubMedGoogle Scholar
• Journee-de Korver JG, Oosterhuis JA, Kakebeeke-Kemme HM, de Wolff-Rouendaal D. Transpupillary thermotherapy (TTT) by infrared irradiation of choroidal melanoma. Doc. Ophthalmol.82(3), 185–191 (1992).
   PubMedGoogle Scholar
• Shields JA, Glazer LC, Mieler WF, Shields CL, Gottlieb MS. Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas. Am. J. Ophthalmol.109(6), 647–655 (1990).
   PubMedGoogle Scholar
• Oosterhuis J, Journee-de Korver HG, Keunen JE. Transpupillary thermotherapy: results in 50 patients with choroidal melanoma. Arch. Ophthalmol.116(2), 157–162 (1998).
   PubMedGoogle Scholar
• Gomer CJ, Rucker N, Ferrario A, Wong S. Properties and applications of photodynamic therapy. Radiat. Res.120(1), 1–18 (1989).
   PubMed Web of Science ®Google Scholar
• Damato BE, Paul J, Foulds WS. Predictive factors of visual outcome after local resection of choroidal melanoma. Br. J. Ophthalmol.77(10), 616–623 (1993).
   PubMed Web of Science ®Google Scholar
• Barbazetto IA, Lee TC, Rollins IS, Chang S, Abramson DH. Treatment of choroidal melanoma using photodynamic therapy. Am. J. Ophthalmol.135(6), 898–899 (2003).
   PubMed Web of Science ®Google Scholar
• Donaldson MJ, Lim L, Harper CA, Mackenzie J, G Campbell W. Primary treatment of choroidal amelanotic melanoma with photodynamic therapy. Clin. Experiment. Ophthalmol.33(5), 548–549 (2005).
   PubMed Web of Science ®Google Scholar
• Shields JA. Local resection of posterior uveal melanoma. Br. J. Ophthalmol.80(2), 97–98 (1996).
   PubMedGoogle Scholar
• Damato BE. Local resection of uveal melanoma. In: Current Concepts in Uveal Melanoma, First Edition. Jager MJ, Desjardins L, Kivelä T, Damato BE (Eds). S Karger, Basel, Switzerland, 66–80 (2011).
   Google Scholar
• Damato BE. Choroidal melanoma endoresection dandelions and allegory-based medicine. Br. J. Ophthalmol.92(8), 1013–1014 (2008).
   PubMed Web of Science ®Google Scholar
• Damato BE, Paul J, Foulds WS. Risk factors for metastatic uveal melanoma after trans-scleral local resection. Br. J. Ophthalmol.80(2), 109–116 (1996).
   PubMed Web of Science ®Google Scholar
• Puusaari I, Damato B, Kivelä T. Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height. Graefes Arch. Clin. Experiment. Ophthalmol.245(4), 522–533 (2007).
   PubMedGoogle Scholar